[Edaily Reporter Kang Min-koo ] AHNLAB,INC.(053800)announced preliminary financial results on the 29th, reporting consolidated revenue of 130.4 billion won and operating profit of 7.3 billion won for the first half of this year.
(Source: AHNLAB,INC.) Revenue increased by 10.9 billion won (9.1%) year-over-year, while operating profit rose by 2.8 billion won (62.3%).
In the second quarter of this year, consolidated revenue was 71.3 billion won, and operating profit was 5.4 billion won. Compared to the same period last year, revenue rose by 9.0 billion won (14.5%), and operating profit increased by 1.9 billion won (55.6%).
AHNLAB,INC. official stated, “Revenue from our global business, centered on our Saudi Arabian joint venture ‘Rakin,’ grew by more than double digits compared to the same period last year,” adding, “Amid growing adoption of N²SF and Zero Trust-related products such as AHNLAB EDR and XTG, we recorded triple-digit revenue growth year-over-year.”
The spokesperson added, “We will continue to strengthen the competitiveness of our AI-based products and services,” and noted, “We will also expand our global business to maintain this robust growth momentum.”
Consolidated financial results for the first half of the year. (Unit: million won) (Source: AHNLAB,INC.)
Business leaders from South Korea and Brazil have agreed to expand cooperation across a wide range of strategic industries, from critical mineral supply chains to artificial intelligence (AI), biotech…
Ingenia Therapeutics (Ingenia), an innovative antibody drug developer set to list on KOSDAQ, has brought a treatment for chronic kidney disease (CKD) to the negotiating table with a global big pharma …
AHNLAB,INC.(053800)announced preliminary financial results on the 29th, reporting consolidated revenue of 130.4 billion won and operating profit of 7.3 billion won for the first half of this year.
…